A deviation from standard design? Clinical trials, research ethics committees, and the regulatory co-construction of organizational deviance

Social Studies of Science

Volumn 44, Issue 1, 2014, Pages 59-81

  Hedgecoe, Adam ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

clinical trials; drug disaster; organizational deviance; research ethics committees

Indexed keywords

EID: 84892868538     PISSN: 03063127     EISSN: 14603659     Source Type: Journal    
DOI: 10.1177/0306312713506141     Document Type: Article

References (94)

1. Abraham J.Partial progress: Governing the pharmaceutical industry and the NHS, 1948-2008.Journal of Health Politics, Policy and Law. 2009;34 (6): 931-977.
2. Abraham J,Davis C.Drug evaluation and the permissive principle: Continuities and contradictions between standards and practices in antidepressant regulation.Social Studies of Science. 2009;39 (4): 569-598.
3. Abraham J,Lewis G.Harmonising and competing for medicines regulation: How healthy are the European Union's systems of drug approval?.Social Science & Medicine. 1999;48 (11): 1655-1667.
4. Abraham J,Reed T.Trading risks for markets: The international harmonisation of pharmaceuticals regulation.Health, Risk and Society. 2001;3 (1): 113-128.
5. Abraham J,Reed T.Progress, innovation and regulatory science in drug development: The politics of international standard-setting.Social Studies of Science. 2002;32 (3): 337-369.
6. Abraham J,Sheppard J.International comparative analysis and explanation in medical sociology: Demystifying the Halcion anomaly.Sociology. 1998;32 (1): 141-162.
7. Abraham J,Sheppard J,Reed T.Re-thinking transparency and accountability in medicines regulation in the United Kingdom.British Medical Journal. 1999;318:46-47.
8. Angell E,Bryman A,Ashcroft RE,Dixon-Woods M.An analysis of decision letters by research ethics committees: The ethics/scientific quality boundary examined.Quality & Safety in Health Care. 2008;17 (2): 131-136.
9. Angell E,Sutton AJ,Windridge K,Dixon-Woods M.Consistency in decision making by research ethics committees: A controlled comparison.Journal of Medical Ethics. 2006;32 (11): 662-664.
10. Ashforth BE,Anand V.The normalization of corruption in organizations.Research in Organizational Behavior. 2003;25:1-52.
11. Early Stage Clinical Trial Taskforce Report. London: Association of British Pharmaceutical Industry and Bioindustry Association; 2006:.
12. The Report of the Committee to Investigate Medical Experiments on Staff Volunteers. London: ABPI; 1970:.
13. Guidelines for Preclinical and Clinical Testing of New Medicinal Products Part 2 - Investigations in Man. London: ABPI; 1977:.
14. Guidelines for Medical Experiments in Non-patient Human Volunteers. London: ABPI; 1988:.
15. Biddle J.Lessons from the Vioxx debacle: What the privatization of science can teach us about social epistemology.Social Epistemology. 2007;21 (1): 21-39.
16. Boseley S,Maley J,Goldenberg S.Doctors call for worldwide help in race to save lives of men who collapsed 'like dominoes' in drug trial.The Guardian. 2006;:7.
17. Boyce MGuidelines for Phase 1 Clinical Trials. London: ABPI; 2007:.
18. Bruneel J,Spithoven A,Maesen A.Building trust: A matter of proximity?.Frontiers of Entrepreneurship Research. 2007;27 (15):.
19. Buoen C,Bjerrum O,Thomsen MS.How first-time-in-human studies are being performed: A survey of phase I dose-escalation trials in healthy volunteers published between 1995 and 2004.Journal of Clinical Pharmacology. 2005;45 (10): 1123-1136.
20. Calder N,Boyce M,Posner J,Sciberras D.Clinical pharmacology studies in UK Phase 1 units: An AHPPI survey 1999-2000.British Journal of Clinical Pharmacology. 2004;57 (1): 76-79.
21. Cambrosio A,Keating P,Schlich T,Weisz G.Biomedical conventions and regulatory objectivity: A few introductory remarks.Social Studies of Science. 2009;39 (5): 651-664.
22. Carvalho FL.Regulation of clinical research and bioethics in Portugal.Bioethics. 2007;21 (5): 290-302.
23. Chalmers I,Glasziou P,Godlee F.Editorial: All trials must be registered and the results published.British Medical Journal. 2013;346:f105.
24. Cromie BW.Testing new medicines in the UK.Journal of the Royal Society of Medicine. 1980;73 (5): 379-380.
25. Curtis P.Drug trial company provisionally cleared by medicines regulator: Disaster could not have been foreseen, says report.The Guardian. 2006;:8.
26. Dahl MS,Pedersen CØR.Knowledge flows through informal contacts in industrial clusters: Myth or reality?.Research Policy. 2004;33 (10): 1673-1686.
27. Decullier E,Chan A,Chapuis F.Inadequate dissemination of phase I trials: A retrospective cohort study.PLoS Medicine. 2009;6 (2): e1000034.
28. Governance Arrangements for NHS Research Ethics Committees. London: Department of Health; 2001:.
29. Dingwall R.Scientific misconduct as organisational deviance.Zeitschrift für Rechtssoziologie. 2001;22 (2): 245-258.
30. Earle JS,Spicer A,Peter KS.The normalization of deviant organizational practices: Wage arrears in Russia, 1991-98.Academy of Management Journal. 2010;53 (2): 218-237.
31. Emanuel EJ,Miller FG.Money and distorted ethical judgments about research: Ethical assessment of the TeGenero TGN1412 Trial.American Journal of Bioethics. 2007;7 (2): 76-81.
32. Expert Scientific Group on Phase One Clinical Trials: Final Report. London: The Stationary Office; 2006:.
33. Fisher JA.Co-ordinating 'ethical' clinical trials: The role of research coordinators in the contract research industry.Sociology of Health & Illness. 2006;28 (6): 678-694.
34. Fisher JAMedical Research for Hire: The Political Economy of Pharmaceutical Clinical Trials. London: Rutgers University Press; 2009:.
35. Gamoran A,Dreeben R.Coupling and control in educational organizations.Administrative Science Quarterly. 1986;31 (4): 612-632.
36. NHS Research Ethics Committee Application for a clinical trial of an investigational medicinal product. 2006 2006;:.
37. Goodyear M.Learning from the TGN1412 trial.British Medical Journal. 2006;332:677-678.
38. Griffin JP,Long JR.New procedures affecting the conduct of clinical trials in the United Kingdom.British Medical Journal. 1981;283:477-479.
39. Hale B.Risk, judgment and fairness in research incentives.The American Journal of Bioethics. 2007;7 (2): 82-83.
40. Harry JD.Research on healthy volunteers: A report of the Royal College of Physicians.British Journal of Clinical Pharmacology. 1987;23 (4): 379-381.
41. Hawkes N.Drug trial errors 'could have been foreseen'.The Times. 2007;:28.
42. Hawkins KLaw as Last Report: Prosecution Decision-making in a Regulatory Agency. Oxford: Oxford University Press; 2002:.
43. Hedgecoe A.Research ethics review and the sociological research relationship.Sociology. 2008;42 (5): 873-886.
44. Hedgecoe A.'A form of Practical Machinery': The origins of Research Ethics Committees in the UK, 1967-1972.Medical History. 2009;53 (3): 331-350.
45. Hedgecoe A.Trust and regulatory organizations: The role of local knowledge and facework in research ethics review.Social Studies of Science. 2012;42 (5): 662-683.
46. Hedgecoe A,Carvalho F,Lobmayer P,Rakar F.Research Ethics Committees in Europe: Implementing the directive, respecting diversity.Journal of Medical Ethics. 2006;32 (8): 483-486.
47. Hope J.No one's to blame.Daily Mail. 2006;:8.
48. Kirsner K,Biddle C.Production pressure and a culture of deviance in the insular operating room and the consequences of their 'normalization': Have we reached a Hooper moment?.The Internet Journal of Law, Healthcare and Ethics. 2012;8 (1):.
49. Knapp P,Raynor DK,Silcock J,Parkinson B.Performance-based readability testing of participant materials for a phase I trial: TGN1412.Journal of Medical Ethics. 2009;35 (9): 573-578.
50. Krimsky SScience in the Private Interest: Has the Lure of Profits Corrupted Biomedical Research?. Lanham, MD: Rowman & Littlefield Publishers; 2003:.
51. Editorial: Expect the unexpected.Lancet Oncology. 2006;7:355.
52. Laurence DR.Decision-taking in drug regulation: Doublethink, regret avoidance, and other matters.Clinical Research and Regulatory Affairs. 1987;5 (5/6): 295-305.
53. Lexchin J.Clinical trials in Canada: Whose interests are paramount?.International Journal of Health Services. 2008;38 (3): 525-542.
54. Lutfullin A,Kuhlmann J,Wensing G.Adverse events in volunteers participating in phase I clinical trials: A single-center five-year survey in 1,559 subjects.International Journal of Clinical Pharmacology and Therapeutics. 2005;43 (5): 217-226.
55. McCaffrey DP,Smith AE,Martinez-Moyano IJ.'Then let's have a dialogue': Interdependence and negotiation in a cohesive regulatory system.Journal of Public Administration Research and Theory. 2007;17 (2): 307-334.
56. Mayor S.Severe adverse reactions prompt call for trial design changes.British Medical Journal. 2006;332:683.
57. Clinical Trial Assessment Report Clinical Data. London: Medicines and Healthcare products Regulatory Agency; 2006a:.
58. Investigations into adverse incidents during clinical trials of TGN1412. London: MHRA; 2006b:.
59. Meyer J,Rowan B.Institutionalized organizations: Formal structure as myth and ceremony.American Journal of Sociology. 1977;83 (2): 340-363.
60. Mirowski P,Van Horn R.The contract research organization and the commercialization of scientific research.Social Studies of Science. 2005;35 (4): 503-548.
61. Nada A,Somberg J.First-in-man (FIM) clinical trials post-TeGenero: A review of the impact of the TeGenero trial on the design, conduct, and ethics of FIM trials.American Journal of Therapeutics. 2007;14 (6): 594-604.
62. Parexel (2005a) REC application form (dated 21 December 2006; received by REC on 4 January 2006).
63. Parexel (2005b) Information sheet, Protocol number: TGN1412-HV. 23 December. Version 01 Final.
64. Clinical Trial Protocol: A phase-I, Single-Centre, Double-Blind, Randomised-Placebo-controlled, single escalating-dose study to assess the safety, pharmacokinetics, pharmacodynamics and immunogenicity of TGN1412 administered intravenously to healthy volunteers. 2006a;:.
65. Parexel (2006b) REC application form, 09/02/2006.
66. Parexel (2006c) Information sheet, Protocol number: TGN1412-HV. 9 February. Version 02 Final.
67. Pautz MC.Trust between regulators and the regulated: A case study of environmental inspectors and facility personnel in Virginia.Politics & Policy. 2009;37 (5): 1047-1072.
68. Petryna AWhen Experiments Travel: Clinical Trials and the Global Search for Human Subjects. Princeton, NJ: Princeton University Press; 2009:.
69. Posner JThe Textbook of Pharmaceutical Medicine. 2005) Exploratory development. In: GriffinJPO'GradyJ (eds) The Textbook of Pharmaceutical Medicine, 5th edn.Malden, MA: Blackwell Publishing, pp. 144-175.Griffin JPO'Grady J, ed. Malden, MA: Blackwell Publishing; 2005:144-175.
70. Rakar FEducation, Labour & Science: Perspectives for the 21st Century. Széll GBösling C-HSzéll U, ed. Frankfurt: Peter Lang International Academic Publishers; 2008:319-330.
71. Clinical Pharmacology in the UK, c. 1950- 2000: Industry and Regulation. Wellcome Witness Twentieth Century Medicine. Reynolds LATansey EM, ed. London: Wellcome Trust.; 2007:.
72. Rose D.Anger as expert report into drug trial disaster fails to allot blame.The Times. 2006;:34.
73. Report of the Working Party on Statistical Issues in First-in-Man studies. London: Royal Statistical Society; 2007:.
74. Savulescu J,Spriggs M.The hexamethonium asthma study and the death of a normal volunteer in research.Journal of Medical Ethics. 2002;28 (1): 3-4.
75. Shah M.Letter from Brent MEC to Parexel. 2006a;:.
76. Shah M.Letter from Brent MEC to Parexel. 2006b;:.
77. Shah M.Extract from Minutes of meeting of Brent MEC. 2006c;:.
78. Sheridan C.TeGenero fiasco prompts regulatory rethink.Nature Biotechnology. 2006;24:475-476.
79. Sibille M,Deigat N,Janin A,Kirkesseli S,Durand DV.Adverse events in phase I studies: A report in 1015 healthy volunteers.European Journal of Clinical Pharmacology. 1998;54 (1): 13-20.
80. Sibille M,Deigat N,Olagnier V,Durand DV,Levrat R.Adverse events in phase I studies: A study in 430 healthy volunteers.European Journal of Clinical Pharmacology. 1992;42 (4): 389-393.
81. Snook SFriendly Fire: The Accidental Shootdown of US Black Hawks over Northern Iraq. Princeton, NJ: Princeton University Press; 2000:.
82. Spielman B.Faulty premise, premature conclusion: That money was extraneous to the research ethics of the TGN1412 study.American Journal of Bioethics. 2007;7 (2): 93-94.
83. Stebbings R,Findlay L,Edwards C,Eastwood D,Bird C,North D, et al.'Cytokine Storm' in the Phase 1 trial of monoclonal antibody TGN1412: Better understanding the causes to improve preclinical testing of immunotherapeutics.Journal of Immunology. 2007;179 (5): 3325-3331.
84. Stobbart L,Murtagh MJ,Rapley T,Ford GA,Louw SJ,Rodgers H.We saw human guinea pigs explode.British Medical Journal. 2007;334:566-567.
85. Sugarman J,Levine C.Letter: Risk in drug trials.Lancet. 2006 2205;368:.
86. Suntharalingam G,Perry M,Ward SJ,Brett S,Castello-Cortes A,Brunner M, et al.Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.The New England Journal of Medicine. 2006;355 (10): 1018-1028.
87. TeGenero (2005) Investigator's Brochure: TGN1412 Humanized Agonistic Anti-CD28 Monoclonal Antibody. Edition 1.1. 2005-12-19. Available at: http://www.circare.org/foia5/tgn1412investigatorbrochure.pdf.
88. Vaughan DControlling Unlawful Organizational Behavior: Social Structure and Corporate Misconduct. Chicago, IL: University of Chicago Press; 1983:.
89. Vaughan DThe Challenger Launch Decision: Risky Technology, Culture and Deviance at NASA. Chicago, IL: University of Chicago Press; 1996:.
90. Vaughan D.The dark side of organizations: Mistake, misconduct, and disaster.Annual Review of Sociology. 1999;25:271-305.
91. Vaughn D.Theorizing the Dark Side. Paper presented at American Journal of Sociology Conference on Causal Thinking and Ethnographic Research; 2012University of Chicago; 2012.
92. Weick KE.Educational organizations as loosely coupled systems.Administrative Science Quarterly. 1976;21 (1): 1-19.
93. Wisely J.National Research Ethics Service: Report to the UKECA on learning and actions taken in response to Northwick Park. 2007a 2007;:.
94. WiselyJ (2007b) National Research Ethics Service: Learning and actions taken in response to the clinical trial of TGN1412. September2007. Available at: http://www.npsa.nhs.uk/easysiteweb/getresource.axd?assetid=62159&type=full&servicetype=att. (accessed 27 September 2013).